Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

FDA Approves 'No-Period' Contraceptive Pill


Related Encyclopedia
 border=
Acidophilus
AIDS and HIV Infection
Amenorrhea
Amniocentesis
More...

Related Healthscout Videos
 border=
Recipe for a Healthy Holiday
Optimistic Healing
Early Babies: How Soon is Too Soon?
Aqua Lipo
More...

Related Animations
 border=
Breast Reduction
Breast Self-Exam Video
Erectile Dysfunction
Facelift
More...

Related Drug Information
 border=
Actonel
Cialis
Detrol LA
Diflucan
More...

Related News Articles
 border=
Vitamin D Deficiency Linked to Cardiovascular Disease
Focusing on School Could Prevent Teen Pregnancies
Low Vitamin D Tied to Estrogen Decline
Caring Through Sharing -- Life Changing Stories
More...


Page:  << Prev | 1 | 2 | 3

But Petriella said many women still feel a strong psychological attachment to their period and do not want to give it up, however inconvenient it may be.

"Sometimes [ending periods] is just emotionally uncomfortable for women," he said. "They don't feel right about not having their period. For those women, obviously Lybrel and other such products are not good products for them."

Petriella believes that, at least in the short-term, Lybrel will appeal to only a minority of women. They include those with menstruation-linked conditions such as endometriosis and menstrual migraine, or those who have already tried -- and liked -- period-limiting products such as Seasonale, he said.

Text Continues Below



As with any pharmaceutical contraceptives, women who decide to go on Lybrel may experience random breakthrough bleeding, Davtyan said.

So, for the 59 percent of women who have no bleeding or spotting after one year, "I think Lybrel is a great deal," Davtyan said. "For the remainder, if they have the patience to hang in there for a few months, the spotting might abate. There will be an occasional patient that will continue to spot, and then, clearly, it's a better deal to have a scheduled period than to start spotting at an unknown time and maybe in an uncomfortable circumstance."

Women who decide to resume their monthly cycle -- for example, those who wish to become pregnant -- can typically expect to resume their normal cycle within days of stopping Lybrel, Shames said. He said that short timespan to resumption of ovulation could leave women who skip or miss pills open to unplanned pregnancy, so the FDA is advising that women consider a second form of birth control while on Lybrel, as a safeguard.

Both Davtyan and Petriella stressed that young women who are considering a pharmaceutical end to their period should not be concerned that doing so will harm their health.

"Remember, there's no real physiological value to hold on to the period that a woman has while she is taking the Pill, unless it is a psychological value, which I respect," Davtyan said.

More information

There's more on various forms of birth control at the U.S. Food and Drug Administration.

Page:  << Prev | 1 | 2 | 3

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 5/23/2007

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake





SOURCES: Camelia Davtyan, M.D., associate professor, medicine, University of California, Los Angeles; Michael Petriella, M.D., vice chairman, department of obstetrics and gynecology, Hackensack University Medical Center, Hackensack, N.J.; May 22, 2007, teleconference with Daniel Shames, M.D., deputy director of the U.S. Food and Drug Administration's Office of Drug Evaluation III, at the Center for Drug Evaluation and Research


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service    
Advertising Policy